Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Kyoto, Kyoto, 606-8507, Japan.
Clinical Genetics Unit, Kyoto University Hospital, Kyoto, Japan.
Int J Hematol. 2023 Sep;118(3):400-405. doi: 10.1007/s12185-023-03575-1. Epub 2023 Mar 10.
Germline mutations in RUNX1 result in rare autosomal-dominant familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML). As genetic analysis is becoming increasingly prevalent, the diagnosis rate of FPD/AML is expected to increase. In this report, we present two pedigrees, one diagnosed molecularly and another highly suspected to be FPD/AML, whose members both received allogeneic hematopoietic stem cell transplantation (HSCT). Both pedigrees had a family history of thrombocytopenia, platelet dysfunction, and hematological malignancies. One family inherited a frameshift mutation (p.P240fs) of RUNX1, a known pathogenic variant. Another family inherited a point mutation (p.G168R) in the runt-homology domain, the clinical significance of which is uncertain at this point. As this mutation was completely absent from all population databases and had a relatively high REVEL score of 0.947, we thought that it would be dangerous to ignore its possible pathogenicity. Consequently, we avoided choosing HSCT donors from relatives of both families and performed HSCT from unrelated donors. In conclusion, our experience with two families of FPD/AML highlights the importance of searching for gene mutations associated with germline predisposition and indicates the necessity of developing a donor coordination system for FPD/AML patients, as well as a support system for families.
RUNX1 种系突变导致罕见的常染色体显性家族性血小板减少伴急性髓系白血病(FPD/AML)。随着基因分析的日益普及,预计 FPD/AML 的诊断率将会增加。在本报告中,我们介绍了两个家系,一个通过分子诊断,另一个高度怀疑为 FPD/AML,其成员均接受了异基因造血干细胞移植(HSCT)。这两个家系都有血小板减少、血小板功能障碍和血液系统恶性肿瘤的家族史。一个家系遗传了 RUNX1 的移码突变(p.P240fs),这是一种已知的致病性变异。另一个家系遗传了 runt-homology 结构域的点突变(p.G168R),目前其临床意义尚不确定。由于该突变完全不存在于所有人群数据库中,且 REVEL 评分相对较高(0.947),我们认为忽略其可能的致病性是危险的。因此,我们避免从两个家系的亲属中选择 HSCT 供者,并从无关供者中进行 HSCT。总之,我们对两个 FPD/AML 家系的经验强调了寻找与种系易感性相关的基因突变的重要性,并表明需要为 FPD/AML 患者开发供者协调系统以及为家庭提供支持系统。